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rEffect of Physician and Hospital Experience on Patient Outcomes for
Endovascular Treatment of Aortoiliac Occlusive Disease
Indes JE, Tuggle CT, Madawat A, et al. Arch Surg 2011;146:966-71.
Conclusion: Hospital and physician volume are predictors of patient
outcome after endovascular treatment of aortoiliac occlusive disease
(AIOD).
Summary: Patients undergoing some vascular and cancer procedures
have a decreased risk of operative death when the procedures are performed
in high-volume hospitals. For many procedures, associations between mor-
tality and hospital volume aremediated through surgeon volume (Birkmeyer
JD et al, N Engl J Med 2002;346:1128-37). Little information is available
on the relationship between physician volume, hospital volume, and the
outcomes of endovascular procedures for AOID. In the study reported here,
the authors evaluated the effects of physician volume, and especially in-
hospital volume, on outcomes of endovascular repair in patients with AIOD.
This was a retrospective, cross-sectional analysis, of in-patients undergoing
endovascular repair of AIOD. Physicians were considered low volume if they
performed 17 procedures per year or high volume if they performed 17
procedures per year. Hospital volume was defined as high (116 procedures
per year) and low (116 procedures per year). The authors identified 818
in-patients who underwent endovascular repair of AIOD from the Health-
care Cost and Utilization Project Nationwide In-patient Sample from Jan-
uary 2003 through December 2007. The main outcome measures were
in-hospital complications and mortality, length of stay, and cost. Of the 818
procedures, 59% were of high-volume physicians who were surgeons, and
65% practiced at high-volume hospitals. Complication rates (unadjusted)
were higher for low-volume compared with high-volume physicians (18.7%
vs 12.6%: P  .02). However, complication rates were not affected by
physician’s specialty or hospital volume. Length of stay was shorter for
patients of high-volume physicians (P  .001), hospitals (P  .001), and
surgeon providers (P  .03). Physician specialty was also associated with
decreased cost (P .004). With multivariate analysis, high physician volume
was associated with lower complications (P  .04), high hospital volume
with shorter length of stay (P  .002), and nonsurgeons with higher costs
(P  .05).
Comment: There are many problems with this report. First, the study
only looked at in-patients; however, the very large majority of patients
undergoing endovascular interventions for AIOD are treated as out-
patients. In addition, this study did not look at the appropriateness of inter-
ventions. High-volume specialists are sometimes associated with a higher
volume of marginal or inappropriate procedures. The study likely represents
a highly skewed sample of patients undergoing endovascular treatment for
AIOD for unclear indications. It is not possible to do a drill down with this
data to determine why shorter lengths of stay might be associated with
higher-volume physicians or why surgeons were associated with lower
hospital costs. It is certainly possible that patients and their risk factors or
complexity of procedure might not have been stratified equally among the
providers and the hospitals. Overall, this article really provides actually little
insight about the relationship between physician and hospital volume for
endovascular treatment of patients with AIOD.
Heart Disease May Be a Risk Factor for Pulmonary EmbolismWithout
Peripheral Deep Venous Thrombosis
Sorensen HT, Horvath-Phuo E, Lash TL, et al. Circulation 2011;124:
1435-41.
Conclusion: Heart disease increases the risk of pulmonary embolism
(PE) not associated with diagnosed deep venous thrombosis (DVT).
Summary: Up to 40% of patients with PE do not have evidence of
DVT (Hull RD, et al, Ann Intern Med 1983;98:91-99). A possible expla-
nation is that the emboli were dislodged from the lower extremity and are
now in the lungs. An additional explanation is that the emboli may come
from another embolic source, including the heart. This may be especially
true in the setting of cardiac disease. Left-sided cardiac thrombi predispose
to arterial embolization. Autopsy series have shown, however, that right-
sided intercardiac thrombosis may be as common as thrombosis on the left
(Ögren M, Eur Heart J 2005;26:1108-14). Echocardiographic studies have
reported right-sided cardiac thrombi in patients with acute PE (Goldhaber
SZ, et al, Mayo Clin Proc 1988;63:1261-4). Recently, it has also been
suggested that there is a higher prevalence of heart disease in patients with
PE and no detected DVT compared with patients who have PE and DVT
(Prandoni P, et al, Eur J Intern Med 2009;20:470-3).The authors sought to determine if cardiac risk factors that increase the
risk of left-sided atrial embolismmay also be associated with an increased risk
o
ef PE without apparent DVT, thereby implicating the heart itself as a
otential source of PE. This was a nationwide, population-based, case-
ontrolled study in Denmark of patients who had a diagnosis of PE or DVT,
r both, between 1980 and 2007. Odds ratios were computed to estimate
elative risk and associated preceding heart disease with PE, PE and DVT, or
VT alone. There were 45,282 patients with PE alone: 4680 with PE and
VT, and 59,790 withDVT alone. An additional 541,561 patients served as
opulation controls. Data indicated that myocardial infarction and heart
ailure in the 3 months before PE conferred a higher risk of apparently
solated PE (OR, 43.5 [95% CI, 39.6-47.8] and 32.4 [29.8-35.2], respec-
ively). The risk of combined PE and DVT (OR 19.7 [95% CI, 16.0-24.2]
nd OR, 22.1 [18.7-26.0] respectively), and DVT alone (OR, 9.6 [8.6-
0.7] and 12.7 [11.6-13.9]) were lower. The OR for left-sided valvular
isease was 13.5 (95% CI, 11.3-16.1). However, the OR for right-sided
alvular disease was 74.6 (95% CI, 28.4-195.8).
Comment: The proportion of apparently isolated PE is much higher in
his study than one would expect. The authors did not have data on how
ften the presence of DVT was assessed in patients with PE. However,
ultiple studies have indicated not everyone with PE has a diagnosable
VT. The authors’ observations on the timing of PE in relationship to
ardiac disease, previous studies indicating a significant prevalence of right-
ided cardiac thrombi, and the strong ORs in this study implicating right-
ided cardiac sources for PE, all combine to suggest the right heart can serve
s a source of PE. A similar analysis performed in patients with PE simulta-
eously assessed for cardiac disease and DVT is needed to determine the
roportion of PEs that originate from the right heart.
ntracranial Hemorrhage IsMuchMore Common After Carotid Stent-
ng Then After Endarterectomy: Evidence From the National Inpatient
ample
cDonald RJ, Cloft HJ, Kallmes DF. Stroke 2011;42:2782-7.
Conclusion: Patients undergoing carotid artery stenting (CAS) are
ore likely to experience intracranial hemorrhage (ICH), in-hospital death,
nd unfavorable discharges relative to those undergoing carotid endarterec-
omy (CEA).
Summary: ICH after carotid revascularization occurs after 0.2% to
.5% of patients (van Mook WN, et al, Lancet Neurol 2005;4:877-88).
ittle data, if any, are available to determine if ICH rates vary between
pecific revascularization procedures. Even large studies, such as CREST,
ack sufficient power to study relative rates of infrequent complications such
s ICH. The National Inpatient Sample (NIS) is a sufficiently large database
o investigate infrequent complications. It provides information with respect
o20% of nonfederal hospitalizations in the United States. This represents
8 million annual hospitalizations (http://www.HCUP-US.AHRQ.
OV/databases.jsp). The authors used the NIS to determine prevalence of,
ype of, and risk factors associated with ICH among recipients of CAS and
EA.
Cases of ICH after CEA or CAS were retrieved from the NIS from 2001
o2008.Clinical presentation (asymptomatic vs symptomatic), discharge status,
n-hospital mortality, demographics, and hospital characteristics were extracted
rom NIS data. ICD-9 and clinical classification software codes were used to
etermine Charlson indices of comorbidity. Multivariate regression analysis
etermined the effect of revascularization procedure type and symptom status
n ICH, in-hospital mortality, and an unfavorable discharge, defined as those
equiring skilled care (short-term hospitalization, skilled nursing facility, home
ealth care).
Among the 57,663,483 NIS hospital admissions were 215,012 CEAs
nd 13,884 CAS procedures. Only 10,049 CEA cases (5%) were considered
ymptomatic, and only 1,251 CAS cases (10%) were for symptomatic
isease. ICH occurred more frequently after CAS than CEA in both symp-
omatic (4.4% vs 0.8%; P .0001) and asymptomatic presentations (0.5% vs
.6%; P  .0001). Multivariate regression indicated that symptomatic
resentation and CAS procedures were independently predictive of a sixfold
o sevenfold increase frequency of postoperative ICH. ICH was in turn
ndependently predictive of a 30-fold increased risk of death before dis-
harge. Among symptomatic patients treated with CAS who developed
CH, the risk for ICH was higher in younger patients.
Comment: The NIS data do not allow independent diagnosis of
yperperfusion among cases of ICHor if hyperperfusion wasmost predictive
f ICH. NIS also contains coding errors, but arguably, such errors occur at
andom so that the data are not biased for or against one procedure or the
ther. The overall dramatic relative increase in ICH in CAS vs CEA patients,
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March 2012886 Abstractspreferential use of CEA in the symptomatic patient to minimize the risk of
adverse neurologic outcome.
Low Prevalence of Abdominal Aortic Aneurysm Among 65-Year-Old
Swedish Men Indicates a Change in the Epidemiology of the Disease
Svensjö S, BjörckM,GürtelschmidM, et al. Circulation 2011;124:1118-23.
Conclusions: There is a lower than expected prevalence of abdominal
aortic aneurysm (AAA) in Swedish men, likely explained by a reduction in
the prevalence of smoking. Changes in the epidemiology of AAA call into
question current abdominal aortic screening algorithms.
Summary: A common recommendation for a screening protocol for
AAA is a one-time ultrasound screening of 65-year-old men. In Sweden,
there has been a rapid introduction of such screening programs (Wanhainen
A, J Vasc Surg 2011;53:1164-5). By 2009, screening programs had been
implemented in five contiguous counties of central Sweden. Every 3months,
65-year-old men in these counties are identified by using a national popu-
lation registry and are then invited to a one-time ultrasound examination of
the abdominal aorta. In 2009, these five counties comprised 15% of Swe-
den’s population (1,404,978 individuals).
In this study, the authors report their results of screening 65-year-old
men for AAA in middle Sweden. All 65-year-old men (n  26,256) in the
five-county area of middle Sweden were identified through a national
population registry and were invited for an ultrasound examination of the
abdominal aorta. An AAA was defined as a maximum infrarenal aortic
diameter 30 mm. Of the 22,187 invited for the screening, 85% accepted
the invitation and 373 AAAs (1.7%, 95% CI, 1.5%-1.9%) were detected. If
one included 127 previously knownAAAs repaired or under surveillance, the
total prevalence of AAA in the population was 2.2% (95% CI, 2.0%-2.4%).
Independent associations from a multivariate logistic regression model with
AAA were self-reported smoking (OR, 3.4; P  .001), coronary artery
disease (OR, 2.0; P  .001), and hypertension (OR, 1.6; P  .001). In the
five-county population, 13% of inhabitants were self-reported to be current
smokers, one-third the frequency reported in the 1980s.
Comment: The population-based study design and high participation
in the screening program (85%) suggests the results of this study are
generally applicable at least to the Swedish population. The prevalence of the
AAA in this study is one-half to one-third of that reported elsewhere and
parallels a dramatic reduction in the prevalence of smoking. The decreased
prevalence of smoking combined with the significant increase in life expec-
tancy of the male population at risk for AAA has implications for AAA
screening programs. On the basis of what is apparently a decreased preva-
lence of disease and decreased risk factors, cost-effectiveness and protocols of
current screening programs may need to be reevaluated.
Nonoperative Management of Adult Blunt Splenic Injury With and
Without Splenic Artery Embolotherapy: A Meta-Analysis
Requarth JA, D’Agostino RB Jr, Miller PR. J Trauma 2011;71:898-903.
Conclusion: Embolization of splenic injury improves the result of
nonoperative management of patients with grade 4 and 5 splenic injuries.
Summary: Nonoperative management of blunt splenic injury (BSI) is
standard of care in hemodynamically stable children (Davis KA, et al,
J Trauma 1998;44:1008-13) and is also frequently used in adults. Nonop-
erative management of BSI can be observational without splenic emboliza-
tion or observational with splenic embolization. The relative effectiveness of
these two approaches stratified for grade of splenic injury is unknown.
Complicating previous studies of the effectiveness of splenic embolization
for treatment of BSI is that purely observational nonoperative management
of BSI is frequently reported along with embolic therapy for splenic injury,
but these are clearly different modes of treatment. The authors point out
that important information comparing the effectiveness of these two forms
of nonoperative management may be lost when the two forms of nonopera-
tive management are studied together or without respect to the specific
grade of splenic injury. This meta-analysis was performed to evaluate the
failure rate of adults with BSI treated with observational management only vs
splenic embolization in patients with comparable grades of injury to the
spleen. The authors reviewed 33 articles on outcomes of BSI published
between 1994 and 2009. Nine publications stratified data by splenic injury
grade for observational management and splenic embolization. The data
from these nine studies were used to analyze failure rates of pure observa-
tional management vs splenic embolization using random effects estimates.
The study comprised 10,157 patients, of whom 68.4% were managed
nonoperatively. The failure rate for nonoperative management was 8.3%
(95% CI, 6.7%-10.2%). The failure rate for observational management alone
increased from 4.7% to 83.1% in patients with splenic injury grades from 1 to
5. The failure rate of splenic embolization was 15.7% (95% CI, 10.4%-
23.2%) and did not vary significantly with splenic injury grades 4 to 5 (P 
.413). In patients with splenic injury grade injuries 4 and 5, the failure rate
of purely observational management without embolization was higher than
failure rates with embolization: 43.7% (95% CI, 25.5%-63.8%) vs 17.3% m95% CI, 7.8%-34.1%, P  .035) and 83.1% (95% CI, 45.2%-96.7%) vs
5.0% (95% CI, 8.7%-53.8%, P  .016), respectively.
Comment: The authors of this study point out that observational
anagement alone and splenic embolization are different methods of non-
perative management of patients with BSI. Comparative information can
e lost when failure rates of the two methods are combined in a single
nalysis. The data here suggest that patients with high-grade splenic injuries
grades 4 and 5) should be treated with embolization if nonoperative
anagement of BSI is chosen.
econdary Prevention and Mortality in Peripheral Artery Disease:
ational Health and Nutrition Examination Study, 1999 to 2004
ande RT, Perlstein TS, Beckman JA, et al. Circulation 2011;124:17-23.
Conclusion: Millions of adults in the U.S. do not receive secondary
reventive therapies for peripheral artery disease (PAD). In patients with
AD, treatment with multiple therapies is associated with reduced all-cause
ortality.
Summary: Lack of evidence for screening-guided treatment in patients
ith PAD has led the U.S. Preventative Services Task Force (USPSFT) to
ecommended against screening for PAD with ankle-brachial index (ABI;
nn Intern Med 2009;151:474-82). This stance has been strengthened by
ecent studies questioning the efficacy of preventive therapies in patients
ith PAD (Berger JS, et al, JAMA 2009;301:1909-19; Fowkes FG, et al,
AMA 2010;303:841-8). Guidelines for management of patients with PAD
ecommend lipid-lowering therapy with a statin, antihypertensive therapy to
chieve a systolic blood pressure 140 mm Hg, particularly angiotensin-
onverting enzyme (ACE) inhibitors, and antiplatelet therapy (Yusuf S, et al,
Engl J Med 2000;342:145-53). Because of inconsistencies for recom-
endations for secondary prevention in patients with PAD, the authors
ought to determine whether treatment with multiple risk factor-modifying
herapies was associated with reduced all-cause mortality in adults identified
ith PAD who otherwise had no established cardiovascular disease. The
uthors analyzed data from the National Health and Nutrition Examination
urvey (NHANES) from 1999 to 2004. Mortality follow-up extended
hrough calendar year 2006. PAD was defined as an ABI 0.90. In the
HANES study, there were 7458 eligible participants aged 40 years with
weighted PAD preference of 5.9%  0.3%. This equates to 7.1 million
dults in the U.S. with PAD. In the NHANES patients, statin use prevalence
as 30.5%  2.5%, ACE inhibitor/angiotensin receptor blocker (ARB) use
revalence was 24.9% 1.9 %, and aspirin use prevalence was 35.8% 2.9%.
his corresponds to 5 million adults in the U.S. with PAD not taking statins,
.4 million not taking ACE inhibitors/ARBs, and 4.5 million not receiving
spirin. Even adjusting for sex, age, and race/ethnicity, PAD was associated
ith all-cause mortality (HR, 2.4; 95% CI, 1.9-2.9; P  .0001). When
ndividuals with PAD were stratified by excluding those with known cardio-
ascular disease, PAD patients still had higher mortality rates of 16.1% 
.1% vs 4.1%  0.3% in subjects without PAD or cardiovascular disease
adjusted HR, 1.9; 95% CI, 1.3-2.8; P  .001). Multiple preventative
herapies in PAD patients without cardiovascular disease were associated
ith 65% lower all-cause mortality (HR, 0.35; 95% CI 0.20-0.86; P .02).
Comment: NHANES is a series of surveys conducted by the National
enter for Health Statistics. The surveys began in the early 1960s; from
999 to 2004, ABI measurements were added. Extrapolating to the U.S.
opulation, potentially thousands of deaths could be avoided if secondary
revention therapies were applied and adhered to in patients with PAD. The
uthors call for a large-scale clinical trial to determine whether implementa-
ion of secondary preventative therapies in patients with PAD identified by
ow ABI can indeed reduce cardiovascular morbidity and mortality. This is
ery reasonable.
upervised Exercise Versus Primary Stenting for Claudication Result-
ng From Aortoiliac Peripheral Artery Disease: Six-Month Outcomes
rom the Claudication: Exercise Versus Endoluminal Revasculariza-
ion (CLEVER) Study
urphy TP, Cutlip DE, Regensteiner JG, et al; and the Clever Study
nvestigators. Circulation 2012;125:130-9.
Conclusion: In patients with intermittent claudication and aortoiliac
isease (AIOD), supervised exercise results in better treadmill walking
erformance than stent revascularization.
Summary: Although drug therapy, revascularization, and supervised
xercise are all documented effective therapies for intermittent claudication,
he relative effectiveness of these measures are unknown. No multicenter
linical trials have directly compared strategies of pharmacology alone or
upervised exercise vs endovascular intervention. The CLEVER trial was a
andomized clinical trial comparing the benefits of optimal medical care,
upervised exercise, and stent revascularization on walking outcomes and
easures of quality of life in patients with intermittent claudication second-
ry to AIOD.The study randomized 111 patients with AIOD to receive optimal
edical care, optimal medical care plus stent revascularization, or optimal
